|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Residual renal function in peritoneal dialysis with failed allograft and minimum immunosuppression显示文摘Immunosuppression(IS) is often withdrawn in patients with end stage renal disease secondary to a failed renal allograft, and this can lead to an accelerated loss of residual renal function(RRF). As maintenance of RRF appears to provide a survival benefit to peritoneal dialysis(PD) patients, it is not clear whether this benefit of maintaining RRF in failed allograft patients returning to PD outweigh the risks of maintaining IS. A 49 year-old Caucasian male developed progressive allograft failure nine years after living-donor renal transplantation. Hemodialysis was initiated via tunneled dialysis catheter(TDC) and IS was gradually withdrawn. Two weeksafter IS withdrawal he developed a febrile illness, which necessitate removal of the TDC and conversion to PD. He was maintained on small dose of tacrolimus(1 mg/d) and prednisone(5 mg/d). Currently(1 year later) he is doing exceedingly well on cycler-assisted PD. Residual urine output ranges between 600-1200 m L/d. Total weekly Kt/V achieved 1.82. RRF remained well preserved in this patient with failed renal allograft with minimal immunosuppressive therapy. This strategy will need further study in well-defined cohorts of PD patients with failed allografts and residual RRF to determine efficacy and safety. | Nadear Elmahi éva Csongrádi Kenneth Kokko Jack R Lewin Jamie Davison Tibor Fülp | 2013 | World Journal of Transplantation2013，3，2： | 5 |
| 2 | Right Ventricular Dysfunction Assessed by Cardiovascular Magnetic Resonance Imaging Predicts Poor Prognosis Late After Myocardial Infarction显示文摘 | Eric Larose Peter Ganz H. Glenn Reynolds Sharmila Dorbala Marcelo F. Di Carli Kenneth A. Brown Raymond Y. Kwong | 2007 | Journal of the American College of Cardiology2007，，8： | 1 |
| 3 | Characterization of the Peri-Infarct Zone by Contrast-Enhanced Cardiac Magnetic Resonance Imaging Is a Powerful Predictor of Post–Myocardial Infarction Mortality显示文摘 | Andrew T. Yan Adolphe J. Shayne Kenneth A. Brown Sandeep N. Gupta Carmen W. Chan Tuan M. Luu Marcelo F. Di Carli H Glenn Reynolds William G. Stevenson Raymond Y. Kwong | 2006 | Circulation2006，，1： | 1 |
| 4 | Fixation of Periprosthetic Femoral Shaft Fractures: A Biomechanical Comparison of Two Techniques显示文摘 | Michael G. Dennis Jordan A. Simon Frederick J. Kummer Kenneth J. Koval Paul E. Di Cesare | 2001 | Journal of Orthopaedic Trauma2001，，3： | 1 |
| 5 | How to minimize infection and thereby maximize patient outcomes in total joint arthroplasty : a multicenter approach : AAOS exhibit selection 显示文摘 | Kenneth DI William M Mihalko J | 2013 | The Journal of bone and joint surgery American vol- ume2013，95，8： | 1 |
| 6 | Single bundle anterior cruciate ligament reconstruction显示文摘 | David JL Daniel H Kenneth DI | 2011 | Techniques in Knee Surgery2011，10，2： | 1 |
| 7 | Radiographic and metabolic response rates following image-guided stereotactic radiotherapy for lung tumors显示文摘 | Nasiruddin Mohammed Inga S. Grills Ching-Yee Oliver Wong Ana Paula Galerani Kenneth Chao Robert Welsh Gary Chmielewski Di Yan Larry L. Kestin | 2011 | Radiotherapy and Oncology2011，，1： | 1 |
| 8 | Use of Dermagraft, a cultured human dermis, to treat diabetic foot ulcers显示文摘 | Gary DG Scott DI Kenneth SH | 1996 | Diabetes Care1996，19，： | 1 |
| 9 | The SCARECROW Gene Regulates an Asymmetric Cell Division That Is Essential for Generating the Radial Organization of the Arabidopsis Root显示文摘 | Laura Di Laurenzio Joanna Wysocka-Diller Jocelyn E Malamy Leonard Pysh Yrjo Helariutta Glenn Freshour Michael G Hahn Kenneth A Feldmann Philip N Benfey | 1996 | Cell1996，，3： | 1 |
| 10 | Dosing strategies for de novo once-daily extended release tacrolimus in kidney transplant recipients based on CYP3A5 genotype显示文摘BACKGROUND Tacrolimus extended-release tablets have been Food and Drug Administrationapproved for use in the de novo kidney transplant population.Dosing requirements often vary for tacrolimus based on several factors including variation in metabolism based on CYP3A5 expression.Patients who express CYP3A5 often require higher dosing of immediate-release tacrolimus,but this has not been established for tacrolimus extended-release tablets in the de novo setting.AIM To obtain target trough concentrations of extended-release tacrolimus in de novo kidney transplant recipients according to CYP3A5 genotype.METHODS Single-arm,prospective,single-center,open-label,observational study(ClinicalTrials.gov:NCT037-13645).Life cycle pharma tacrolimus(LCPT)orally once daily at a starting dose of 0.13 mg/kg/day based on actual body weight.If weight is more than 120%of ideal body weight,an adjusted body weight was used.LCPT dose was adjusted to maintain tacrolimus trough concentrations of 8-10 ng/mL.Pharmacogenetic analysis of CYP3A5 genotype was performed at study conclusion.RESULTS Mean time to therapeutic tacrolimus trough concentration was longer in CYP3A5 intermediate and extensive metabolizers vs CYP3A5 non-expressers(6 d vs 13.5 d vs 4.5 d;P=0.025).Mean tacrolimus doses and weight-based doses to achieve therapeutic concentration were higher in CYP3A5 intermediate and extensive metabolizers vs CYP3A5 non-expressers(16 mg vs 16 mg vs 12 mg;P=0.010)(0.20 mg/kg vs 0.19 mg/kg vs 0.13 mg/kg;P=0.018).CYP3A5 extensive metabolizers experienced lower mean tacrolimus trough concentrations throughout the study period compared to CYP3A5 intermediate metabolizers and non-expressers(7.98 ng/mL vs 9.18 ng/mL vs 10.78 ng/mL;P=00.008).No differences were identified with regards to kidney graft function at 30-d post-transplant.Serious adverse events were reported for 13(36%)patients.CONCLUSION Expression of CYP3A5 leads to higher starting doses and incremental dosage titration of extended-release tacrolimus to achieve target trough concentrations.We suggest a higher starting dose of 0.2 mg/kg/d for CYP3A5 expressers. | Adam Diamond Sunil Karhadkar Kenneth Chavin Serban Constantinescu Kwan N.Lau Oscar Perez-Leal Kerry Mohrien Nicole Sifontis Antonio Di Carlo | 2023 | World Journal of Transplantation2023，13，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员